Wednesday, July 1, 2020

MBS2320 at the EULAR 2020 Online Meeting


MBS2320 might have escaped your attention. In 2019 there had been a poster at the EULAR Annual Meeting and this year there should have been an oral presentation.
MBS2320 is a novel selective modulator of immune metabolism. I haven't found much elucidation of what the compound selectively modulates [1]. The study I'll talk about here says: „MBS2320 is a selective modulator of immune metabolism displaying distinctive dual pharmacology: strong anti-inflammatory activity as well as a broader spectrum of osteoprotection than TNFα inhibition in preclinical models.“ [2] It is a reference to the poster presentation a year ago, both times L. Patel has been the first author. Adis Insight has as most recent event: „13 Aug 2019 / Modern Biosciences completes a phase IIa trial in Rheumatoid arthritis (Adjunctive treatment) in Moldova, Romania and Georgia (NCT03139136) (EudraCT2016-004038-24)“ [3]. So, we're really up to date.

L. Patel and colleagues presented the following study [2]: „OP0234 MBS2320, A NOVEL SELECTIVE MODULATOR OF IMMUNE METABOLISM, IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY.“ It's a phase 2 study with dose escalation of MBS2320 after 4 weeks from 80mg to 120mg in patients, who tolerated 80 mg. The study lasted for 12 weeks. Of the 121 randomized patients only 96 completed the study; that's a loss of about 21%. The results show an increase of response rates in the verum group, but aren't comparable to other studies. Authors' conclusions: „MBS2320 was generally well tolerated for up to 12 weeks in this RA study population. Nausea was the most common TEAE, was generally mild in severity and resolved without treatment. In this population of patients with hardtotreat, severe, active, erosive disease MBS2320 showed evidence of a clinical benefit on both ACR20 responses and DAS28-CRP.“

I'm always happy if new novel mechanisms of action in anti-rheumatic drugs make it into phase 2 and 3 studies. Will there be a drug in coming years? Hard to tell as we lack precise information on the mode of action. I'd wish to have a comparator like a biologic agent or another small molecule like a JAK-inhibitor. I guess that there will be. Hopefully we don't have to wait too long.


Links and References:
[2] L. Patel1, L. Skillern1, M. Foster1, A. Gray1, R. Leff2, S. Williams1. 1Istesso Ltd,
London, United Kingdom; 2Richard Leff LLC, Philadelphia, United States of America. OP0234 MBS2320, A NOVEL SELECTIVE MODULATOR OF IMMUNE METABOLISM, IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY. DOI: 10.1136/annrheumdis-2020-eular.3804.

.

No comments:

Post a Comment